Cardiovascular Risk Factors in an Ambulatory Urban Patient Population (AsuRiesgo)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Derliz Mereles, University of Heidelberg
ClinicalTrials.gov Identifier:
NCT00486993
First received: June 12, 2007
Last updated: February 24, 2014
Last verified: February 2014

June 12, 2007
February 24, 2014
May 2006
May 2014   (final data collection date for primary outcome measure)
cardiovascular mortality [ Time Frame: one year ]
Same as current
Complete list of historical versions of study NCT00486993 on ClinicalTrials.gov Archive Site
  • mortality, other causes [ Time Frame: one year ]
  • acute myocardial infarction [ Time Frame: one year ]
  • stroke [ Time Frame: one year ]
  • acute coronary syndrome [ Time Frame: one year ]
Same as current
Not Provided
Not Provided
 
Cardiovascular Risk Factors in an Ambulatory Urban Patient Population
Estimation of Prevalence and Assessment of the Effects of Modification of Cardiovascular Risk Factors in an Ambulatory Urban Patient Population

According to WHO estimations, cardiovascular diseases (CVDs) are the number one cause of death globally. More people die annually from CVDs than from any other cause. An estimated 17.5 million people died from CVDs in 2005, representing 30% of all global deaths. Of these deaths, an estimated 7.6 million were due to coronary heart disease and 5.7 million were due to stroke.

Over 80% of CVD deaths take place in low- and middle-income countries and occur almost equally in men and women. In Paraguay, prevalence of classic risk factors, as well as new ones, like the metabolic syndrome are not completely known.

Government health policies in industrialized countries are focusing on programs to modify cardiovascular risk factors. In developing countries, prevention of coronary heart disease and stroke through modification of cardiovascular risk factors are not playing a large role at the moment.

The aim of this study is to define the effects of changes in lifestyle on cardiovascular risk factors, when added to optimized standard pharmacological therapy for arterial hypertension, diabetes mellitus and hyperlipidemia, in an ambulatory urban patient population.

Not Provided
Interventional
Not Provided
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
  • Cardiovascular Risk Factors
  • Metabolic Syndrome
  • Lifestyle Modification
  • Coronary Artery Disease
  • Stroke
  • Behavioral: Dietary and nutritional modification
  • Behavioral: Stop smoking
  • Behavioral: Regular physical activities
  • Behavioral: Weight reduction to normal ranges
  • Behavioral: Regular intake of polyphenols, esp. from Ilex paraguayensis
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
7000
May 2016
May 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • all ambulatory patients, with age 18 years or older

Exclusion Criteria:

  • no exclusion criteria provided, particularly for the first, epidemiological part of the study
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Paraguay
 
NCT00486993
AsuRiesgo
Yes
Derliz Mereles, University of Heidelberg
Heidelberg University
Not Provided
Principal Investigator: Derliz Mereles, MD Heidelberg University
Heidelberg University
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP